Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: Comparison with metformin

Diabetologia

Volumn 47, Issue 7, 2004, Pages 1306-1313

  Ye, J M ^a   Dzamko, N ^a   Cleasby, M E ^a   Hegarty, B D ^a   Furler, S M ^a   Cooney, G J ^a   Kraegen, E W ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Adipose tissue; AMP activated protein kinase; Biguanides; Fatty acid kinetics; Insulin resistance; Liver; Muscle; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE PHOSPHATE; ADIPONECTIN; BIGUANIDE DERIVATIVE; FATTY ACID; GLUCOSE; GLYCEROL; HEPARIN; INSULIN; LONG CHAIN FATTY ACID COENZYME A LIGASE; METFORMIN; PALMITIC ACID DERIVATIVE; PALMITOYL COENZYME A HYDROLASE; PROTEIN KINASE; ROSIGLITAZONE; TRIACYLGLYCEROL; TRITIUM;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL METABOLIC RATE; BODY WEIGHT; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FATTY ACID TRANSPORT; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID LIVER LEVEL; LIPID METABOLISM; MALE; MUSCLE LEVEL; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT;

EID: 4143075930     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1436-1     Document Type: Article

References (37)

1. McGarry JD (1992) What if Minkowski had been ageusic? An alternative angle on diabetes. Science 258:766-770
2. Spiegelman BM (1998) PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514
3. Moller DE (2001) New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414:821-827
4. Hevener AL, He W, Barak Y et al. (2003) Muscle-specific PPARg deletion causes insulin resistance. Nat Med 9:1491-1497
5. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW (1994) A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-1210
6. Oakes ND, Bell KS, Furler SM et al. (1997) Diet-induced muscle insulin resistance in rats is ameliorated by acute dietary lipid withdrawal or a single bout of exercise - parallel relationship between insulin stimulation of glucose uptake and suppression of long-chain fatty acyl-CoA. Diabetes 46:2022-2028
7. Zhou YT, Grayburn P, Karim A et al. (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 97:1784-1789
8. Shimabukuro M, Zhou YT, Lee Y, Unger RH (1998) Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273:3547-3550
9. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH (1999) Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA 96:11513-11518
10. Combs TP, Wagner JA, Berger J et al. (2002) Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143:998-1007
11. Yamauchi T, Kamon J, Ito Y et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769
12. Oakes ND, Thalen PG, Jacinto SM, Ljung B (2001) Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50:1158-1165
13. Ye JM, Frangioudakis G, Iglesias MA et al. (2002) Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver. Endocrinology 143:4527-4535
14. Oakes ND, Kjellstedt A, Forsberg GB et al. (1999) Development and initial evaluation of a novel method for assessing tissue-specific plasma free fatty acid utilization in vivo using (R)-2-bromopalmitate tracer. J Lipid Res 40:1155-1169
15. Knowler WC, Barrett-Connor E, Fowler SE et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
16. Zhou G, Myers R, Li Y et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174
17. Ruderman NB, Saha AK, Kraegen EW (2003) Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology 144:5166-5171
18. Kemp BE, Stapleton D, Campbell DJ et al. (2003) AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 31:162-168
19. Fisher JS, Gao J, Han DH, Holloszy JO, Nolte LA (2002) Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol 282:E18-E23
20. Iglesias MA, Ye JM, Frangioudakis G et al. (2002) AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin resistant high-fat fed rats. Diabetes 51:2886-2894
21. Kraegen EW, James DE, Jenkins AB, Chisholm DJ (1985) Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol 248:E353-E362
22. Kraegen EW, James DE, Storlien LH, Burleigh KM, Chisholm DJ (1986) In vivo insulin resistance in individual peripheral tissues of the high fat fed rat: assessment by euglycaemic clamp plus deoxyglucose administration. Diabetologia 29:192-198
23. James DE, Burleigh KM, Kraegen EW (1985) Time dependence of insulin action in muscle and adipose tissue in the rat in vivo. An increasing response in adipose tissue with time. Diabetes 34:1049-1054
24. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-917
25. Antinozzi PA, Segall L, Prentki M, McGarry JD, Newgard CB (1998) Molecular or pharmacologic perturbation of the link between glucose and lipid metabolism is without effect on glucose-stimulated insulin secretion. A re-evaluation of the long-chain acyl-CoA hypothesis. J Biol Chem 273:16146-16154
26. Davies SP, Carling D, Hardie DG (1989) Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay. Eur J Biochem 186:123-128
27. Hevener AL, Reichart D, Janez A, Olefsky J (2001) Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male Wistar rats. Diabetes 50:2316-2322
28. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW (2001) Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 50:411-417
29. Kraegen E, Cooney G, Ye JM, Furler S (2002) Peroxisome proliferator activated receptors, fatty acids and muscle insulin resistance. J R Soc Med 95:14-22
30. Frayn KN (2002) Adipose tissue as a buffer for daily lipid flux. Diabetologia 45:1201-1210
31. Way JM, Harrington WW, Brown KK et al. (2001) Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269-1277
32. Norris AW, Chen L, Fisher SJ et al. (2003) Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112:608-618
33. Thalen P, Frangioudakis G, Camejo G et al. (2003) Contribution of circulating triglyceride to fatty acid loading in individual tissues in vivo. Diabetes 52 [Suppl 1]:A9 (abstract)
34. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM et al. (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15:5336-5348
35. Lefebvre AM, Peinado-Onsurbe J, Leitersdorf I et al. (1997) Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol 17:1756-1764
36. Shachter NS (2001) Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 12:297-304
37. Ye JM, Iglesias MA, Watson DG et al. (2003) PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol 284:E531-E540